News Archive

31 Oct 2017
Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30 Jun 2017
Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung
16 Jun 2017
Johnson & Johnson Completes Acquisition of Actelion
14 Jun 2017
Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson
09 Jun 2017
Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange
09 Jun 2017
Johnson & Johnson announces expected settlement of Actelion tender offer on June 16, 2017
08 Jun 2017
Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD
22 May 2017
Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia
15 May 2017
Actelion announces changes to its executive team upon completion of the transaction with Johnson & Johnson
27 Apr 2017
Publication of the definitive notice of the end result of Actelion tender offer
24 Apr 2017
Publication of the provisional notice of the end result of Actelion tender offer
10 Apr 2017
Actelion amends its financial reporting schedule
05 Apr 2017
Actelion's Annual General Meeting of Shareholders 2017
31 Mar 2017
Johnson & Johnson publishes interim result for Actelion tender offer and declares the tender offer successful
15 Mar 2017
Actelion issues invitation to 2017 Annual General Meeting of Shareholders
07 Mar 2017
Actelion is granted marketing authorization by the European Commission for Ledaga (chlormethine gel) for the treatment of MF-CTCL
02 Mar 2017
Actelion obtains "Epoprostenol ACT" label extension for pediatric PAH patients in Japan
16 Feb 2017
Johnson & Johnson publishes prospectus for Actelion tender offer
14 Feb 2017
Actelion announces excellent financial results for 2016
10 Feb 2017
Actelion concludes second line share repurchase program